These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36373163)

  • 1. Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer.
    He WZ; Wang L; Yin CX; Yi JH; Jin YN; Jiang C; Guo GF; Xia LP
    Cancer Med; 2023 Mar; 12(6):6488-6498. PubMed ID: 36373163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
    Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
    Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
    Yang Y; Xu L; Wang D; Hui B; Li X; Zhou Y; Chen X; Gu Y
    Immunotherapy; 2021 Nov; 13(16):1317-1323. PubMed ID: 34369830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.
    Xu YJ; Zhang P; Hu JL; Liang H; Zhu YY; Cui Y; Niu P; Xu M; Liu MY
    World J Gastrointest Oncol; 2022 Apr; 14(4):920-934. PubMed ID: 35582108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
    Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
    Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
    Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
    Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
    Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
    Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.
    Xu D; Liu Y; Tang W; Xu L; Liu T; Jiang Y; Zhou S; Qin X; Li J; Zhao J; Ye L; Chang W; Xu J
    Front Oncol; 2022; 12():838870. PubMed ID: 35433423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
    BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.